The MMRF Blog - Multiple Myeloma Research Foundation

The MMRF Blog

ASCO Educational Session: Consolidation and Maintenance: Moving Beyond Autotransplant

The learning objectives for this session included: 1. Describing optimal approaches and evidence-based data outlining the role of consolidation therapy after autologous transplant. 2. Discussing when and how to choose maintenance approaches, including the duration of therapy. 3. Identifying which patients are best suited for an allogeneic transplant approach, and current clinical trials that are making successful headway. READ MORE

Posted: June 09, 2016

Day Three Wrap-Up: ASCO 2016

Last year daratumumab (Darzalex) received accelerated approval by the U.S. Food and Drug Administration to treat myeloma patients that had at least three prior therapies. Daratumumab was the first human monoclonal antibody to be approved for the treatment of myeloma. READ MORE

Posted: June 07, 2016

Day Two Sessions: ASCO 2016

The MMRF/MMRC team is spending nearly a week at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting and we are pleased to share with you some key highlights from the multiple myeloma (MM) data presented. The oral session this morning attracted a large crowd of attendees, so there was much anticipation for the data! READ MORE

Posted: June 04, 2016

Page 24 of 87« First...10...2223242526...304050...Last »